Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.
Also called NCT02769481
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 426 participants
- Sponsor
- Registry
-
NCT02769481
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Poland, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02769481. Randomized; quadruple masking; primary purpose treatment. Start 2016-08-15 (actual); primary completion 2019-06-14 (actual). Results posted on 2021-05-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Bexagliflozin
- Intervention (Drug)
- Placebo for Bexagliflozin
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Placebo for Glimepiride
- Lead sponsor
- Theracos
Record details
- Record id
cardio:ct-nct02769481- Content hash
2e9043194f4d63c2478050a7c2bcb2459c1b1761a6846ac1ba5e2979938ca5eb